Name: Eric Meizlish
New title: CEO, Cardiosense
Previous title: CEO, Prendio-BioProcure
Cardiosense has hired Eric Meizlish as CEO to oversee the growth of its recently cleared wearable heart monitor.
The company, which disclosed the appointment last week, has recruited Meizlish to replace co-founder Amit Gupta as CEO. Gupta will continue as chief strategy officer. Cardiosense has made the change as it enters a new phase in its growth, with the focus now on driving sales of the CardioTag heart monitor and launching artificial intelligence models that pair with the device.
Meizlish has experience leading companies through similar phases. Cardiosense highlighted the new CEO’s track record of building growth-stage companies and driving partnerships. Meizlish was co-founder and president of Lumere, a health data and analytics company that Global Healthcare Exchange bought in 2020, and most recently worked as CEO of life science procurement platform Prendio-BioProcure.
Daniel Gottlieb, director at Cardiosense investor Broadview Ventures, said in a statement that hiring a new CEO is an important step in the company’s evolution as it scales its platform. Gottlieb added that Meizlish is the right leader to accelerate Cardiosense’s momentum.
Meizlish forms part of a new-look leadership team. Cardiosense appointed John Martin as chief medical officer last month. Martin was previously chief medical officer emeritus at ultrasound company Butterfly Network. As a practicing vascular surgeon, Martin will bring cardiology expertise to Cardiosense’s work on clinical development and product strategy.
Gupta, who co-founded Cardiosense in 2020, will work with Meizlish and Martin in his role as chief strategy officer. The former CEO said in a statement that Meizlish’s “leadership and proven track record scaling in healthtech companies make him the right person to lead us going forward.”
Cardiosense’s switch to a leader with experience scaling healthtech companies comes as it works to build on the recent 510(k) clearance of CardioTag. The Food and Drug Administration cleared the device in July, positioning Cardiosense to launch a wearable that enables physicians to noninvasively monitor a patient’s cardiac function. The company is developing AI algorithms to interpret the wearable data.
